I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The  company  Novo  Nordisk  A/S  submitted  on  7  November  2002  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Levemir, 
in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to 
Council Regulation No (EEC) 2309/93 of 22 July 1993, as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr. M. Ainsworth 
Co-Rapporteur: Dr F. Lekkerkerker 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 November 2002. 
The  Rapporteur's  and  Co-Rapporteur’s  first  Assessment  Reports  were  circulated  to  all  CPMP 
members on 31 January 2003. 
During  the  meeting  on  18-20  March  2003  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 March 2003. 
The applicant submitted the responses to the CPMP consolidated List of Questions on 13 May 
2003 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on  23 June 2003. 
During the CPMP meeting on 22-24 July 2003, the CPMP agreed on a list of outstanding issues 
to be addressed in an oral explanation and/or in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding issues to all CPMP members on 3 December 2003. 
During the CPMP meeting on 16-17 December 2003, the CPMP agreed on a list of outstanding 
issues to be addressed in an oral explanation and/or in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding issues to all CPMP members on 4 February 2004. 
During  the  CPMP  meeting  on  25  February  2004,  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation before the CPMP. 
During  the  meeting  on  24-26  February  2004,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  Levemir  on  26  February  2004.  The  applicant  provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  26 
February 2004. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 1 June 2004. 
II  GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION 
1.  Manufacturing Authorisation Holder  
Manufacturer of the active substance 
CHMP/0936/04 
1/2 
EMEA 2004 
 
 
Novo Nordisk A/S 
Novo Allé 
DK-2880 Bagsvaerd 
Denmark 
Manufacturer of the finished product 
Novo Nordisk A/S 
Novo Allé 
DK-2880 Bagsvaerd 
Denmark 
Manufacturer responsible for import and batch release in the European Economic Area 
Novo Nordisk A/S 
Novo Allé 
DK-2880 Bagsvaerd 
Denmark 
Manufacturing authorisation issued on October 2002 by the Danish Medicines Agency. 
2. 
Conditions or restrictions regarding supply and use 
Medicinal product subject to medical prescription. 
3. 
Specific obligations of the Marketing Authorisation Holder 
As requested by the CPMP, the Applicant agreed to address a number of follow-up measures within an 
agreed timeframe. 
CHMP/0936/04 
2/2 
EMEA 2004 
 
